Earlier meta-analyses did report a small on-medication motor benefit, roughly one to three points, but that effect is heterogeneous and fragile: in at least one pooled analysis, it lost statistical significance once the lixisenatide trial was removed [8]
No additional datasets were deposited in external public repositories
Therefore, the choice between Mounjaro vs Ozempic in type 2 diabetes should depend on medical advice as well as individual treatment goals
Furthermore, when the trials were analysed according to the included populations (patients with or without T2DM), the results were similar (patients with T2DM: SMD 0.32
doi:10.1016/S0083-6729(01)61003-3
In this article, you will get: A complete, scannable peptide dosage chart with beginner, standard, and advanced doses